Abstract
We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%).
Publication types
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antigens, CD / immunology
-
Bone Marrow / radiation effects
-
Cell Adhesion Molecules / immunology
-
Hematopoietic Stem Cell Transplantation / methods*
-
Humans
-
Immunoconjugates / administration & dosage*
-
Leukemia / therapy*
-
Middle Aged
-
Radioisotopes / therapeutic use
-
Rhenium / therapeutic use
-
Transplantation Conditioning / methods
-
Transplantation, Homologous
Substances
-
Antigens, CD
-
CD66 antigens
-
Cell Adhesion Molecules
-
Immunoconjugates
-
Radioisotopes
-
Rhenium